Tumor-Bearing Status Accelerates Bleomycin-Induced Pulmonary Inflammation via Endothelial Activation

Area of Science:

• Oncology
• Pulmonology
• Toxicology

Background:

• Drug-induced lung disease (DILD) is a serious side effect of cancer therapy.
• Clinical observations suggest a link between DILD and tumor progression, but mechanisms are unknown.

Purpose of the Study:

• To investigate the role of tumor-bearing status in the development and severity of DILD.

Main Methods:

• Established Lewis lung carcinoma (LLC) and KLN205 tumor models in mice.
• Administered bleomycin (BLM) to induce DILD.
• Assessed endothelial activation markers (PAI-1, vWF, ICAM-1), inflammatory cell infiltration, and alveolar wall thickness.
• Examined the involvement of high-mobility group box 1 (HMGB1).

Main Results:

• Tumor-bearing mice showed increased endothelial activation markers and lung inflammatory cell infiltration.
• BLM treatment in tumor-bearing mice led to more severe lung inflammation and endothelial activation compared to BLM alone.
• Elevated serum HMGB1 levels were observed in tumor-bearing mice.
• HMGB1 administration increased lung inflammation and endothelial activation.

Conclusions:

• Tumor-bearing status primes the lungs for increased inflammation and endothelial activation.
• This preclinical state exacerbates DILD induced by chemotherapy agents like bleomycin.